Royalty Pharma plc (NASDAQ: RPRX) Stock Competitors & Peer Comparison

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while CORT trades at $113.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas CORT's P/E ratio is 325.37. In terms of profitability, RPRX's ROE is +0.12%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RPRX is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CORT's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas WBA's P/E ratio is -1.64. In terms of profitability, RPRX's ROE is +0.12%, compared to WBA's ROE of -0.42%. Regarding short-term risk, RPRX is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check WBA's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, KNSA has a market cap of 6.1B. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while KNSA trades at $78.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas KNSA's P/E ratio is 88.67. In terms of profitability, RPRX's ROE is +0.12%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, RPRX is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check KNSA's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, LQDA has a market cap of 6B. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while LQDA trades at $67.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas LQDA's P/E ratio is 483.50. In terms of profitability, RPRX's ROE is +0.12%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, RPRX is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check LQDA's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, PBH has a market cap of 2.5B. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while PBH trades at $52.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas PBH's P/E ratio is 11.87. In terms of profitability, RPRX's ROE is +0.12%, compared to PBH's ROE of +0.09%. Regarding short-term risk, RPRX is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PBH's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, LTGO has a market cap of 1.5B. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while LTGO trades at $24.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas LTGO's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to LTGO's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check LTGO's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas HROWL's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, RPRX is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check HROWL's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas HROWM's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, RPRX is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check HROWM's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, HELP has a market cap of 755M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while HELP trades at $12.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas HELP's P/E ratio is -2.92. In terms of profitability, RPRX's ROE is +0.12%, compared to HELP's ROE of -0.71%. Regarding short-term risk, RPRX is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check HELP's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas SVA's P/E ratio is -5.68. In terms of profitability, RPRX's ROE is +0.12%, compared to SVA's ROE of -0.01%. Regarding short-term risk, RPRX is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check SVA's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, CUVL has a market cap of 310.6M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while CUVL trades at $6.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas CUVL's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to CUVL's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CUVL's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, CELG-RI has a market cap of 244.7M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, RPRX is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CELG-RI's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, HITI has a market cap of 220.6M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while HITI trades at $2.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas HITI's P/E ratio is -7.36. In terms of profitability, RPRX's ROE is +0.12%, compared to HITI's ROE of -0.43%. Regarding short-term risk, RPRX is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check HITI's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas ATLN's P/E ratio is -0.68. In terms of profitability, RPRX's ROE is +0.12%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, RPRX is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check ATLN's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, CTOR has a market cap of 72.1M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while CTOR trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas CTOR's P/E ratio is -1.65. In terms of profitability, RPRX's ROE is +0.12%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, RPRX is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CTOR's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, SDEV has a market cap of 47.8M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while SDEV trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas SDEV's P/E ratio is -0.17. In terms of profitability, RPRX's ROE is +0.12%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, RPRX is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SDEV's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas RAD's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to RAD's ROE of +2.76%. Regarding short-term risk, RPRX is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check RAD's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, NSRX has a market cap of 34.9M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while NSRX trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas NSRX's P/E ratio is -5.62. In terms of profitability, RPRX's ROE is +0.12%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, RPRX is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check NSRX's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas GLTO's P/E ratio is -1.78. In terms of profitability, RPRX's ROE is +0.12%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, RPRX is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check GLTO's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, SCYX has a market cap of 34M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while SCYX trades at $5.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas SCYX's P/E ratio is -1.58. In terms of profitability, RPRX's ROE is +0.12%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, RPRX is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SCYX's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, CNSY has a market cap of 21M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while CNSY trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas CNSY's P/E ratio is -0.42. In terms of profitability, RPRX's ROE is +0.12%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, RPRX is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CNSY's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, BFRI has a market cap of 20.4M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while BFRI trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas BFRI's P/E ratio is -2.89. In terms of profitability, RPRX's ROE is +0.12%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, RPRX is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BFRI's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, SCNX has a market cap of 16M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while SCNX trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas SCNX's P/E ratio is -0.16. In terms of profitability, RPRX's ROE is +0.12%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, RPRX is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SCNX's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, BFRIW has a market cap of 14.2M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while BFRIW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, RPRX's ROE is +0.12%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, RPRX is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BFRIW's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, COSM has a market cap of 12.2M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while COSM trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas COSM's P/E ratio is -0.30. In terms of profitability, RPRX's ROE is +0.12%, compared to COSM's ROE of -1.19%. Regarding short-term risk, RPRX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check COSM's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas CJJD's P/E ratio is -0.46. In terms of profitability, RPRX's ROE is +0.12%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, RPRX is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check CJJD's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas SSY's P/E ratio is -2.86. In terms of profitability, RPRX's ROE is +0.12%, compared to SSY's ROE of -0.09%. Regarding short-term risk, RPRX is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check SSY's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, POM has a market cap of 6.4M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while POM trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas POM's P/E ratio is -0.19. In terms of profitability, RPRX's ROE is +0.12%, compared to POM's ROE of +0.16%. Regarding short-term risk, RPRX is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check POM's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while BGMS trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas BGMS's P/E ratio is -0.25. In terms of profitability, RPRX's ROE is +0.12%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, RPRX is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BGMS's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, PAVS has a market cap of 4.1M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while PAVS trades at $4.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas PAVS's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, RPRX is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PAVS's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas MDVL's P/E ratio is -0.05. In terms of profitability, RPRX's ROE is +0.12%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, RPRX is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check MDVL's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas ATNFW's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, RPRX is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check ATNFW's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, RPRX's ROE is +0.12%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, RPRX is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check BGMSP's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas AZNH's P/E ratio is 38.35. In terms of profitability, RPRX's ROE is +0.12%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, RPRX is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check AZNH's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, RPRX's ROE is +0.12%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, RPRX is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check LFLYW's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, PRPH has a market cap of 295.7K. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while PRPH trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas PRPH's P/E ratio is -0.01. In terms of profitability, RPRX's ROE is +0.12%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, RPRX is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check PRPH's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, CPD has a market cap of 0. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas CPD's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to CPD's ROE of N/A. Regarding short-term risk, RPRX is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check CPD's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, OREX has a market cap of 0. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas OREX's P/E ratio is -0.14. In terms of profitability, RPRX's ROE is +0.12%, compared to OREX's ROE of -0.54%. Regarding short-term risk, RPRX is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check OREX's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas ESRX's P/E ratio is 10.69. In terms of profitability, RPRX's ROE is +0.12%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, RPRX is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check ESRX's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas SHPG's P/E ratio is 11.35. In terms of profitability, RPRX's ROE is +0.12%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, RPRX is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for RPRX.Check SHPG's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, POZN has a market cap of 0. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas POZN's P/E ratio is N/A. In terms of profitability, RPRX's ROE is +0.12%, compared to POZN's ROE of +0.61%. Regarding short-term risk, RPRX is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check POZN's competition here

Royalty Pharma plc (NASDAQ: RPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RPRX stands at 27B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, RPRX is priced at $60.85 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RPRX currently has a P/E ratio of 11.59, whereas IPXL's P/E ratio is -10.11. In terms of profitability, RPRX's ROE is +0.12%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, RPRX is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for RPRX.Check IPXL's competition here